Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Phase 1

Completed

Brief Summary: The purpose of this study is to determine whether iobenguane I 131 is safe and effective in patients with malignant pheochromocytoma or paraganglioma.

Detailed Description: This was originally designed as a phase 1/2 study. The phase 1 patients received a small dose of study drug to see if the tumors absorb the drug. If the patient's tumors absorbed the drug, then the patient received one therapeutic dose. In the phase 1 portion, the study employed a 3 + 3 dose escalation design. Enrollment in the phase 1 portion was to be completed once researches believed that they found the highest dose that they could give patients without causing unacceptable toxicity. This dose is called the maximum tolerated dose (MTD). Following discussions with the Food and Drug Administration (FDA) that occurred during the dose escalation stage of the study, the protocol was amended to conclude the trial upon the identification of the MTD. The Phase 2 safety/ efficacy stage of the study was conducted with modifications of the primary endpoint as Protocol MIP IB12B, with Special Protocol Assessment Agreement with the FDA in March 2009.

Recruitment & Eligibility

Inclusion Criteria

Have a diagnosis of either adrenal pheochromocytoma or extra-adrenal paraganglioma by histological confirmation OR plasma-free metanephrines and 24-hour urine test for catecholamines/ metanephrines
Disease is metastatic or has recurred following surgery
At least one measurable lesion seen by computed tomography (CT) or magnetic resonance (MR) scan performed within 4 weeks prior to the first dose of study drug
At least one known tumor site is also seen on Ultratrace iobenguane I 131 scan
Provide written informed consent and are willing to comply with protocol requirements
Are at least 18 years of age
If female, then not of childbearing potential as documented by history (e.g., tubal ligation or hysterectomy) or is post menopausal with a minimum 1 year without menses
If female of childbearing potential, has a negative serum b-HCG pregnancy test within 48 hours prior to receiving iobenguane I 131
Females who agree not to become pregnant and males who agree not to father a child during the 1 year period following the therapeutic dose of Ultratrace iobenguane I 131. Both females and males must use an acceptable method of birth control during the first year following the therapeutic dose of Ultratrace iobenguane I 131.

Exclusion Criteria

Females who are nursing
Active CNS lesions by CT/MR scanning within 3 months of study entry
New York Heart Association class III-IV heart failure
Received any previous systemic radiotherapy within 6 months of study entry
Administered prior whole-body radiation therapy
Received external beam radiotherapy to greater than 25 percent of bone marrow
Administered prior chemotherapy within 30 days of study entry
Karnofsky performance status is less than 60
Platelets are less than 100,000/uL
Absolute neutrophil count (ANC) is less than 1,500/uL
Serum creatinine is greater than 1.5 mg/dL
Total bilirubin is greater than 1.5 times the upper limit of normal
AST/SGOT or ALT/SGPT is greater than 2.5 times the upper limit of normal
Has received a therapeutic investigational compound and/or medical device within 30 days before admission into this study
Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post dose follow-up examinations
Is determined by the Investigator that the patient is clinically unsuitable for the study.
Has received a medication which inhibits uptake of iobenguane I 131:
phenothiazines or decongestants within 2 weeks prior to enrollment; or,
a tricyclic antidepressant within 6 weeks prior to enrollment.

Arm && Interventions

Group	Intervention	Description
Dose Escalation	Ultratrace Iobenguane (MIBG) I 131	Dosing of Ultratrace iobenguane I 131 began at 6.0 mCi/kg and escalated in 1.0 mCi/kg increments in order to establish the MTD. The MTD is the dose immediately below the level at which escalation stops due to dose-limiting toxicity (DLT). An additional 3 patients are to be treated at the MTD, for a total of 6.

Primary Outcome Measures

Name	Time	Method
MTD of Ultratrace Iobenguane I 131	6 weeks post therapy dose	Although no primary efficacy endpoint was defined for this study, the MTD of Ultratrace iobenguane I 131 in patients with malignant pheochromocytoma/paraganglioma (a safety rather than an efficacy parameter) is the primary objective.

Secondary Outcome Measures

Name	Time	Method

Locations (3): New York Presbyterian Hospital-Weill Cornell Medical Center
🇺🇸
New York, New York, United States
Duke University Medical Center
🇺🇸
Durham, North Carolina, United States
Rhode Island Hospital
🇺🇸
Providence, Rhode Island, United States